June 2022 Top Biopharma Deal: Sanofi – Regeneron Pharmaceuticals for Cancer/Inflammation drug Libtayo
June 2022 Top Biopharma Deal Upfront
Sanofi development and commercialization deal with Regeneron for Libtayo (Amended Agreement)
Highlighted Deal Financial Comps
Date Announced:
June 2, 2022
Total Deal Value:
$1,100M
Upfront Cash:
$900M
Upfront Equity:
n/a
Option Payments:
n/a
Total Milestones:
$200M
Royalties:
11% royalties on worldwide net sales
Cost & Profit Split:
n/a
Deal Synopsis
The Asset:
Sanofi’s first line treatment: Libtayo for cancer
Deal Structure:
Development and Commercial License
Partnership Features:
License Hand-Off
Deal Details:
- Sanofi granted Regeneron exclusive, worldwide rights to develop and commercialize Libtayo for the treatment of cancer. Sanofi and Regeneron signed a license agreement in 2015 to develop Libtayo.
- Per the 2015 agreement, Regeneron would book sales in the US, and Sanofi would be responsible for the rest of the world. The companies would share profits equally (see separate deal profile). In June 2022, the companies signed a new agreement where Sanofi will transfer its rights to develop and commercialize Libtayo to Regeneron. The ex-US transaction is expected to close in Q3 2022.
- Sanofi will receive $900M up front and is eligible to receive up to a $100M milestone upon the first approval by either the FDA or EMA for Libtayo in combination with chemotherapy for first-line treatment of certain patients with NSCLC, and up to $100M as a sales milestone in the next two years, plus 11% royalties.
Last Month:
Congrats to Sanofi and Regeneron for landing DealForma’s June 2022 Top Biopharma Deal. Last month’s Deal of the Month was Dragonfly Therapeutics – Gilead Sciences NK cell engager for cancer/inflammation treatment. Read about it here.
DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.
We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.
20,378
Licensing Deals
17,730
Funding Rounds
4,034
M&A
31,012
Company Profiles
5,478
Other Deals
26,505
Drug Sales Figures
All of this by stage, disease indication, modality, target...
More Research by DealForma
Introducing: DealForma plus Tableau
We are excited to introduce DealForma's new Tableau dashboard integration. High quality data on biopharma deals and funding meets interactive charts and visuals. DealForma customers will have exclusive access to the DealForma chart dashboards built on Tableau right...
Venture & IPO – Medtech – Q1 2023
The Medtech sector encompasses medical devices, diagnostics, and digital health solutions, playing a crucial role in healthcare. In Q1 2022, the medtech, devices, digital health therapeutics, and wearables sector experienced a strong opening with 95 funding rounds and...